Discussion stirs around Retrophin Inc (NASDAQ:RTRX) this week; here is what analysts are saying.

October 12, 2017 - By Clifton Ray

 Discussion stirs around Retrophin Inc (NASDAQ:RTRX) this week; here is what analysts are saying.
Investors sentiment increased to 1.16 in Q2 2017. Its up 0.18, from 0.98 in 2017Q1. It increased, as 13 investors sold Retrophin Inc shares while 31 reduced holdings. 13 funds opened positions while 38 raised stakes. 39.61 million shares or 0.01% more from 39.61 million shares in 2017Q1 were reported.
The Switzerland-based Swiss Bank & Trust has invested 0% in Retrophin Inc (NASDAQ:RTRX). 600,000 were reported by Lombard Odier Asset Mgmt (Usa) Corporation. Barclays Plc reported 2,172 shares. Moreover, Rhumbline Advisers has 0% invested in Retrophin Inc (NASDAQ:RTRX) for 47,454 shares. Franklin Resource Inc owns 1.04M shares for 0.01% of their portfolio. Wells Fargo And Com Mn has invested 0% in Retrophin Inc (NASDAQ:RTRX). Schwab Charles Inv Management reported 0.01% stake. Spark Mngmt Ltd Llc reported 277,110 shares stake. Price T Rowe Associate Md owns 0% invested in Retrophin Inc (NASDAQ:RTRX) for 344,794 shares. Northern Trust accumulated 708,248 shares or 0% of the stock. Manufacturers Life Ins The has invested 0% in Retrophin Inc (NASDAQ:RTRX). Deutsche Comml Bank Ag has invested 0.01% of its portfolio in Retrophin Inc (NASDAQ:RTRX). Voya Mngmt Ltd Liability Co has 17,905 shares. Moreover, Sphera Funds Mgmt Limited has 0.69% invested in Retrophin Inc (NASDAQ:RTRX) for 209,131 shares. 59,424 are owned by Nationwide Fund Advsr.

Since June 14, 2017, it had 1 insider buy, and 0 sales for $89,250 activity.

Retrophin Inc (NASDAQ:RTRX) Ratings Coverage

Among 4 analysts covering Retrophin (NASDAQ:RTRX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Retrophin had 6 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets on Friday, October 6 with “Buy”. The stock of Retrophin Inc (NASDAQ:RTRX) has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. Zacks downgraded Retrophin Inc (NASDAQ:RTRX) on Wednesday, August 12 to “Buy” rating. JMP Securities initiated the shares of RTRX in report on Monday, November 2 with “Mkt Outperform” rating. Below is a list of Retrophin Inc (NASDAQ:RTRX) latest ratings and price target changes.

06/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $44.0 Maintain

About 36,470 shares traded. Retrophin Inc (NASDAQ:RTRX) has risen 4.93% since October 12, 2016 and is uptrending. It has underperformed by 11.77% the S&P500.

Retrophin, Inc. is a biopharmaceutical company. The company has market cap of $936.41 million. The Firm is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It currently has negative earnings. The Firm sells three products, including Chenodal , Cholbam (cholic acid) and Thiola (tiopronin).

Another recent and important Retrophin Inc (NASDAQ:RTRX) news was published by Globenewswire.com which published an article titled: “Retrophin Announces Presentation of New Data from Physician-Initiated …” on October 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.